



OPEN ACCESS

EDITED BY
Bingdong Zhu,
Lanzhou University, China

REVIEWED BY
Rajeev K. Tyagi,
Institute of Microbial Technology
(CSIR), India
Xudong Wang,
National Vaccine and Serum
Institute, China

*CORRESPONDENCE
Haibo Feng
✉ fenghaiborc@126.com

SPECIALTY SECTION
This article was submitted to
Vaccines and Molecular Therapeutics,
a section of the journal
Frontiers in Immunology

RECEIVED 10 October 2022
ACCEPTED 12 December 2022
PUBLISHED 04 January 2023

CITATION
Feng Y, Tang F, Li S, Wu D, Liu Q, Li H,
Zhang X, Liu Z, Zhang L and Feng H
(2023) Mannose-modified erythrocyte
membrane-encapsulated chitovanic
nanoparticles as a DNA vaccine carrier
against reticuloendothelial tissue
hyperplasia virus.
Front. Immunol. 13:1066268.
doi: 10.3389/fimmu.2022.1066268

COPYRIGHT
© 2023 Feng, Tang, Li, Wu, Liu, Li,
Zhang, Liu, Zhang and Feng. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus

Yangyang Feng^{1,2}, Feng Tang^{1,2}, Sheng Li^{1,2}, Daiyan Wu^{1,2},
Qianqian Liu^{1,2}, Hangyu Li^{1,2}, Xinnan Zhang^{1,2}, Ziwei Liu^{1,2},
Linzi Zhang^{1,2} and Haibo Feng^{1,2*}

¹College of Animal Husbandry and Veterinary Medicine, Southwest Minzu University, Chengdu, China, ²Key Laboratory of Ministry of Education and Sichuan Province for Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization, Southwest-Minzu University, Chengdu, China

Introduction: The erythrocyte membranes used in nanovaccines include high membrane stability, long circulation life, adaptability and extremely good bio compatibility. Nanoparticles encapsulated by erythrocyte membranes are widely used as ideal drug delivery vehicles because of their high drug loading, long circulation time, and excellent biocompatibility. The mannose modification of delivery materials can help target mannose receptors (MRs) to deliver antigens to antigen-presenting cells (APCs).

Methods: In this study, the antigen gene gp90 of avian reticuloendotheliosis virus (REV) was encapsulated with carboxymethyl chitosan (CS) to obtain CSgp90 nanoparticles, which were coated with mannose-modified fowl erythrocyte membranes to yield CS-gp90@M-M nanoparticles. The physicochemical characterization and immune response of the CS-gp90@M-M nanoparticles were investigated *in vitro* and *in vivo*.

Results: CS-gp90@M-M nanoparticles were rapidly phagocytized *in vitro* by macrophages to induce the production of cytokines and nitric oxide. *In vivo*, CS-gp90@M-M nanoparticles increased cytokine levels, the CD4+/8+ ratio, REV-specific antibodies in the peripheral blood of chicks, and the mRNA levels of immune-related genes in the spleen and bursa of immunized chicks. CS-gp90@M-M nanoparticles could be targeted to lymphoid organs to prolong the retention time of the nanoparticles at the injection site and lymphatic organs, leading to a strong, sustained immune response. Moreover, the CS-gp90@M-

M nano-vaccine showed a lasting immunoprotective effect and improved the body weight of chicks after the challenge.

Conclusion: Overall, CS-gp90@M-M nanoparticles can be used in vaccine designs as an effective delivery carrier with immune response-enhancing effects.

KEYWORDS

reticuloendothelial virus bionic, chitosan, erythrocyte membrane, mannose modification, delivery system

1 Highlights

1. The mannose receptor targeted Biomimetic REV nucleic acid vaccine (CS-gp90@M-M) were constructed for the first time.
2. CS-gp90@M-M significantly promoted the immune activity of macrophage in vitro.
3. CS-gp90@M-M could effectively activate the immune system and offer immune protection against REV challenge in chicks.
4. CS-gp90@M-M can slow release in injection site and stay longer in the immune organs in chicks.
5. CS-gp90@M-M could effectively promote humoral and cellular immune responses.

2 Introduction

Avian reticuloendothelial hyperplasia virus (REV) has a worldwide prevalence and chicks, ducks, turkeys, and other poultry are sensitive to this virus (1). REV can cause acute reticular cell tumor formation dwarfism syndrome, and chronic tumors of lymphoid and other tissues. REV infection also causes immunosuppression and decreases the immune efficacy of other vaccines, leading to infected chickens that are prone to secondary bacterial and other viral infections, with significant economic losses to the poultry industry. Currently, there is no effective commercial vaccine available to prevent this disease (2, 3).

Nanoparticle carriers show immense potential in vaccine development (4, 5). Bionic nanoparticles wrapped around cell membranes are a drug delivery vehicle with the combined advantages of synthetic nanoparticles and natural cell membranes. As highly abundant circulating cells in vertebrates, erythrocytes perform the special function of capturing certain pathogens in the blood and presenting them to the immune cells in secondary immune organs. Thus,

erythrocytes are a kind of natural “innate carrier” with many unique advantages in drug delivery (6). Erythrocyte membranes can be used as an encapsulating material to decorate nanoparticles as delivery vehicle systems with the advantages of long circulation, high membrane flexibility and stability (7), good biocompatibility (8), the retention of basic cellular functions, and functional groups that can be modified on the membrane surface (9). Owing to these special advantages, the use of erythrocytes as biomimetic drug nanomaterials to treat diseases and modulate immune function shows great potential.

In gene therapy, the structural characteristics of the target gene and the physiological barrier function of the body make it difficult to effectively target specific cells and organs. This process can be completed with the help of vectors (10). Chitosan is a nontoxic and harmless nano-material prepared from the deacetylation of natural polysaccharides. Positively charged chitosan can combine with negatively charged drugs to increase drug stability (11, 12). Currently, the main drawback of chitosan as a gene delivery system is its limited solubility under physiological conditions and low effective transfection efficiency. Thus, methylated carboxymethyl chitosan (C₂₀H₃₇N₃O₁₄) is used as a cell membrane core to wrap nanoparticles. Carboxymethyl chitosan can be obtained under alkaline conditions. The substitution of carboxymethyl will occur on both -OH and -NH to form O-carboxymethyl and N-carboxymethyl chitosan. Carboxymethyl chitosan is not only soluble in water because it is a sodium carboxylate salt, but also because the introduction of carboxymethyl destroys the secondary structure of the chitosan molecules, so their crystallinity is greatly reduced and the material almost becomes amorphous (13). CS has higher water solubility at physiological pH, facilitating nanoparticle synthesis and rendering it more suitable for drug delivery and biological imaging (14).

Mannose receptors (MRs) belong to the C-type lectin receptor superfamily and are widely distributed on the membranes of dendritic cells (DCs) and macrophages. MRs play a crucial role in pathogen recognition and homeostasis. MRs can also recognize mannose residue-conjugated adjuvants

and drug-delivery materials. Many studies have been designed to improve the immune response of cell membrane-encapsulated nanoparticles, where mannose was commonly used as the targeted ligand for specific targeting to antigen-presenting cells (APCs) (15).

We hypothesized that erythrocyte membrane encapsulation and mannose-targeted modification could enhance the immunogenicity of nanoparticles, while chitosan could enhance the gene-carrying capacity of nanodrug delivery systems. Therefore, the current study aimed to investigate the immune response of mannose-modified erythrocyte membrane-coated chitosan bionic nanoparticles and evaluate their potential application in the development of poultry vaccines.

3 Materials and methods

3.1 Materials

Phosphatidyl ethanolamine-polyethylene glycol-mannose (DSPE-PEG-Mannose) was obtained from Shanghai Yanyi Biology Co., Ltd. (Shanghai, China). Carboxymethyl chitosan (deacetylation degree: 85%; MW:600 kDa) was purchased from Xi'an Baichuan Biotechnology Co., Ltd. (Xi'an, Shanxi, China). The nitric oxide (NO) test kit, lipophilic fluorescent DiD dye, 4',6-diamidino-2-phenylindole (DAPI) DNA fluorescent dye, the chicken lymphocyte separation kit, and Methylthiazolyldiphenyl-tetrazolium bromide (MTT) were procured from Beijing Solarbio Technology Co., Ltd. (Beijing, China). The REV antibody kit, interferon (IFN)- γ , and interleukin (IL)-4 enzyme-linked immunosorbent assay (ELISA) kits were obtained from Jiangsu Meimian Industry Co., Ltd. (Nanjing, Jiangsu, China). Mouse anti-chicken CD4⁺-FITC and CD8⁺-PE antibodies were procured from eBioscience (San Diego, CA, USA). Avian reticuloendotheliosis virus (CVCC: CVCCAV107) was purchased from the Chinese Veterinary Microbial Strain Preservation and Management Center.

3.2 Preparation of CS-gp90@M-M nanoparticles

The pTT5-gp90 recombinant plasmid (Nanjing, Jiangsu, China) was prepared according to the plasmid extraction kit instructions and purified using PEG8000 following a previously published study (16). Briefly, 250 μ g/mL of carboxymethyl chitosan and 100 μ g/mL of pcDNA-gp90 plasmid solution were mixed, stirred for 30 s, and stored at 25 °C for 1 h (17). The collected blood was centrifuged at 1500 \times g for 3 min at 4°C, and the serum was removed. The erythrocytes were soaked for 20 min in

an osmotic phosphate-buffered saline (PBS) ice bath and collected by centrifugation. After 3 washes, the erythrocyte membranes were resuspended in PBS and mixed with CS-gp90 for 18 h at 4°C (18). The solutions were combined and passed 20 times through a liposome extruder with a 200-nm pore diameter filter membrane, and then centrifuged to remove excess erythrocyte membranes. After stirring for 1 h, 0.1 mg/mL of DSPE-PEG-MAN solution was added to insert mannose into the erythrocyte membranes to yield mannose-embedded chicken erythrocyte membranes.

3.3 Physicochemical properties of CS-gp90@M-M nanoparticles

Agarose gel electrophoresis was used to detect whether the gp90 gene was correctly inserted into the plasmid. The ultra-microstructure of the erythrocyte membrane-encapsulated nanoparticles (CS-gp90@M-M) was observed using transmission electron microscopy (TEM) (FEI, Tecnai G2 F20 S-TWIN, CA, USA) and the images were photographed. DSPE-PEG-Man, CS-gp90@M, and CS-gp90@M-M spectra were obtained using Fourier-transform infrared (FT-IR) spectroscopy (8400S, Shimadzu Co., Nakagyo-ku, Kyoto, Japan). IR spectra were recorded and analyzed in the range of 400 to 4000 cm^{-1} . CS-gp90@M and CS-gp90@M-M samples were mounted on glass slides and analyzed using Raman spectroscopy (Horiba, LabRAM, France) at 532 nm in the range of 1000 – 2000 cm^{-1} . The particle size and polymer dispersity index (PDI) of the nanoparticles were determined using a laser particle-size analyzer. Various nanoparticles were simultaneously placed in a potential cup to measure their zeta potential. A standard curve of a CS-gp90 solution was constructed, and the absorbance of the samples was measured at 470 nm. The CS-gp90 concentration in the supernatant was determined using the standard curve. The adsorption rate and drug-loading rate were calculated using formulas (1) and (2) (19).

$$\begin{aligned} \text{Drug - loading rate (\%)} \\ &= (\text{CS - gp90 mass} - \text{CS} \\ &\quad - \text{gp90 mass in the supernatant}) / \text{carrier total mass} \\ &\quad \times 100 \% \end{aligned} \tag{1}$$

$$\begin{aligned} \text{Entrapment efficiency (\%)} \\ &= (\text{CS - gp90 mass} - \text{CS} \\ &\quad - \text{gp90 mass in the supernatant}) / \text{drug dosage} \\ &\quad \times 100 \% \end{aligned} \tag{2}$$

3.4 *In vitro* experiments

3.4.1 Cytotoxicity of CS-gp90@M-M nanoparticles

In vitro cytotoxicity tests were performed using the MTT method (20). Briefly, 2×10^4 /mL HD11 cells were added to 96-well cell culture plates and treated with various concentrations of CS-gp90@M and CS-gp90@M-M nanoparticles at 40 °C. After 24 h, 100 μ L of medium and 10 μ L of MTT (5 mg/mL) were added for 4 h and the supernatant was aspirated after a purple precipitate was formed. Next, 150 μ L of dimethyl sulfoxide was added to each well. The absorbance of each well was determined using a microplate reader (Bio-Rad, iMark, Hercules, CA, USA) at 570 nm.

3.4.2 Uptake of CS-gp90@M-M nanoparticles by HD11 cells

Cell uptake assay. HD11 cell solution (1 mL) at a concentration of 8×10^4 cells/mL was added to a 24-well plate, and 50 μ L of DiD-stained CS-gp90@M and CS-gp90@M-M (200 μ g/mL) nanoparticles were filtered. After incubation for 8 h in the dark, the culture medium was discarded, and the cells were washed twice with PBS, stained with DAPI dye, and washed twice for 20 min. A drop of anti-fluorescence quenching agent was added to the cells on a clean slide. The slide was analyzed using confocal laser scanning microscopy (CLSM) (ZEISS, Oberkochen, Germany).

Quantitative test to determine cell uptake activity. DiD-stained CS-gp90@M (50 μ L) and CS-gp90@M-M (200 μ g/mL) nanoparticles were incubated with 5×10^5 HD11 cells in a Petri dish for 8 h. The intracellular fluorescence intensity of DiD was measured using a small animal *in vivo* imager (Perkin Elmer IVIS LuminaIII, Waltham, MA, USA).

3.4.3 NO secretion and iNOS mRNA expression

Cells in the logarithmic growth phase were seeded in a 24-well cell culture plate at a density of 1×10^6 cells/mL. Based on the concentration of the plasmid, 100 μ g/mL of the nanoparticle solutions prepared using 1 mL of DMEM basic culture medium (PBS group, gp90 plasmid group, CS-gp90 nanoparticle group, CS-gp90@M nanoparticle group, CS-gp90@M-M nanoparticle group) and the positive lipopolysaccharide (LPS) control (1 μ g/mL) were cultured for 24 h. The nitric oxide (NO) content was determined using an NO detection kit (Nanjing, China). The absorbance was determined using a microplate reader at 540 nm, and the NO concentration was calculated using the standard gradient curve. Total RNA was extracted from each group of cells using an RNA extraction kit for cDNA synthesis. The level of inducible nitric oxide synthase (iNOS) mRNA was analyzed

using a real-time polymerase chain reaction detection system (CFX96, Bio-Rad).

3.5 *In vivo* experiments

3.5.1 Animal immunization

Sixty 1-day-old Dehua black chicks without REV were purchased from the Chengdu animal market in Sichuan Province and fed adaptively for 3 days. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Southwest Minzu University and the Institutional Animal Care and Use Committee of Southwest Minzu University (IACUC approval No.: IACUC-20211012-21). The chicks were randomly divided into 5 groups (PBS group, gp90 plasmid group, CS-gp90 nanoparticle group, CS-gp90@M nanoparticle group, and CS-gp90@M-M nanoparticle group). Based on entrapment efficiency and drug loading, the drug was injected into the leg muscle at a dose of 1 μ g/g body weight. Chicks in the PBS group were administered an equal volume of sterilized PBS in the same manner, and booster immunization was performed on day 14 after the first immunization. Chicks from the different groups were raised in separate cages. Blood from the subtalar vein was collected every week and used to determine various indices after anticoagulation.

3.5.2 Antibody ELISA

Serum was obtained from the peripheral blood of immunized chicks collected at 0 – 5 weeks, and serum antibody titers were determined using an enzyme-linked immunosorbent assay (ELISA) antibody detection kit for REV. The optical density (OD) of the samples was determined at 450 nm. Antibody titers were calculated based on the statistical analysis of the data (S/P value, S represents sample OD value; P represents positive hole OD value).

3.5.3 Cytokine assays

After 21 days following the first immunization, 3 chicks in each group were randomly selected and blood was collected from the inferior wing vein. The serum was separated and stored at -20 °C until further use. Serum cytokine levels of IFN- γ and IL-4 were determined using the corresponding ELISA kits following the manufacturer's instructions.

3.5.4 T lymphocyte subsets

On the 21st day after primary immunization, 3 chicks per group were randomly selected and 1 mL of blood was collected. Isolated lymphocytes (2×10^6 cells/mL; 50 μ L) were stained using

mouse anti-chicken CD3⁺-allophycocyanin (APC), CD4⁺-fluorescein isothiocyanate (FITC), and CD8⁺-phycoerythrin (PE) fluorescent antibodies. The percentage of CD4⁺ and CD8⁺ T lymphocytes in T cells was measured by fluorescence-activated cell sorting (FACS; BD FACSVerserTM, CA, USA), and the ratio of CD4⁺/CD8⁺T cells was calculated (21).

3.5.5 Detection of immune-related molecules by qRT-PCR

The mRNA level of Interferon induced with helicase C domain 1 Protein (IFIH1), interferon regulatory factor 7 (IRF7), toll-like receptor (TLR)3, signal transducer and activator of transcription 1 (STAT1), viperin, IFN- γ , and IL-4 were determined by qRT-PCR. An RNA extraction kit was used to extract RNA from the spleen and bursa tissues of chicks on the 21st day of the experiment. Spare tissues (30 mg) from each group were pulverized in a mortar and quickly ground with liquid nitrogen. The remaining steps were the same as those listed in Section 2.4.3.

3.5.6 Delivery kinetics of the constructed nano-vaccines

After adaptive feeding, chicks were randomly selected and intramuscularly injected with one of the DiD-stained nano-vaccines (CS-gp90@M and CS-gp90@M-M nanoparticles) at a dose of 10 μ g/g body weight. Biomimetic nanoparticles labeled with DiD at different time points (0, 6, 12, 24, 48, and 72 h) after


immunization were detected using a PerkinElmer IVIS Lumina III *in vivo* imaging system. To quantify the biomimetic nanoparticles in different tissues and organs, we used a small animal *in vivo* imaging system to determine the fluorescence intensity of chicken organs in an *ex-vivo* study.

3.5.7 Protective effects of CS-gp90@M-M nanoparticles against REV infection

One hundred and eighty chicks were randomly divided into 5 groups, and 36 chicks in each group were randomly divided into 3 batches, with 12 chicks per batch. A challenge test was performed on the 3rd, 15th, and 30th days after vaccination. Chicks were intraperitoneally infected with a 100-fold dilution of the 50% tissue culture infectious dose (TCID₅₀ REV (TCID₅₀ = 10-4.62/0.1 mL) and then reared in isolation. Cumulative mortality was calculated 21 days after the challenge, and the changes in the body weight of the chicks in each group were determined at the same time.

3.5.8 Observation of the toxicity of CS-gp90@M-M nanoparticles

On the 28th day of the experiment, 3 chicks from each group were randomly selected, and their kidneys, spleens, lungs, livers, and hearts were collected. Paraformaldehyde solution (4%) was used to fix the collected samples. Tissues were embedded in paraffin, sectioned, stained with hematoxylin and eosin (H&E), sealed, and observed using microscopy.



3.6 Statistical analysis

The results are presented as the mean \pm standard deviation ($n=3$). The data were analyzed using SPSS 22 (SPSS, Chicago, IL, USA). Differences between the groups were analyzed using the Duncan test and (Least-Significant Difference) LSD multiple comparisons tests. A P -value of < 0.05 was considered significantly significant.

4 Results

4.1 Characterization

4.1.1 The construction of CS-gp90

In this study, the products of digested plasmid DNA and HindIII/SmaI analyzed using 1% agarose gel electrophoresis showed obvious bands around 950 bp, consistent with the expected results, indicating that the *gp90* gene was correctly inserted into the pTT5 plasmid (Figure 1A). The complexation and condensation of DNA in polyplexes with chitosan was studied by using agarose gel electrophoresis. The results demonstrated that the migration speed of CS-gp90 in electrophoresis was significantly slower than that of gp90, indicated that the complexation and condensation of DNA and chitosan in the polymer increase the molecular weight of gp90 (Figure 1B).

4.1.2 Membrane proteins analysis


Membrane proteins are the main component of erythrocyte membranes. Erythrocyte membrane-coated nanoparticles (CS-gp90@M and CS-gp90@M-M) showed a significant increase in protein content compared to exposed nanoparticles, resulting in and the protein content of both types of nanoparticles was similar (Figure 1C).

4.1.3 TEM morphological characteristics

The micro morphology of CS-gp90 NPs was observed as round or oval solid particles with uniform distribution and no aggregation (Figure 1D). The CS-gp90@M-M nanoparticles were round and spherical. A layer of red cell membranes was wrapped around the nanoparticles, and their surface was shell-like erythrocyte membranes with a typical shell-core structure (Figure 1E).

4.1.4 FT-IR spectroscopy and raman spectrum analysis

The FT-IR infrared spectroscopy results are shown in Figure 1F. The FT-IR spectra of the mannose, CS-gp90@M, and CS-gp90@M-M were determined during the 4000 to 400 cm^{-1} range, and the results are shown in Figure 1E. The FT-IR spectrum of CS-gp90@M-M exhibits all the property peaks of CS-gp90@M, including a broadly intense stretched peak in the 3200 to 3600 cm^{-1} regions representing to hydroxyl and amino absorption peak stretching vibrations, and the specific absorption peak of methyl and methylene stretching vibrations was detected in the 2884 cm^{-1} region. A peak between 1500 and 1600 cm^{-1} indicated C=O asymmetric stretching vibrations. The absorption peaks around the 900 to 1200 cm^{-1} region is the C–O–C stretching vibration absorption corresponding glucose characteristics. Furthermore, the asymmetric stretching peaks in the 1276, 1168, 1095, and 960 cm^{-1} regions as the same absorption peaks as observed in CS-gp90@M. The other absorption peaks, in the 1454 and 1388 cm^{-1} regions, exhibited two absorption peaks of mannose. The results show that the CS-gp90@M-M obtained some characteristics of mannose, revealing that the mannose modification was successful (22). As there are no functional groups of mannose in simple erythrocyte membranes, it could be concluded that mannose-targeted erythrocyte membranes were successfully synthesized. This finding was also confirmed based on the



characteristic peak shift in the Raman spectrum. The erythrocyte membrane nanoparticles were characterized using transmission electron microscopy (Figure 1G).

4.1.5 Particle size, zeta potential, and PDI analysis

However, compared to the expected particle size, the measured size was relatively small, likely due to drying and dehydration during TEM. Combined with the findings from transmission electron microscopy, the successful encapsulation of the nanoparticles in erythrocyte membranes was confirmed. After coating with the cell membranes, the diameter of the CS-gp90@M nanoparticles increased slightly. Moreover, the particle size of CS-gp90@M nanoparticles increased after DSPE-PEG-Man modification, likely due to the polyethylene glycol chain anchored on the nanoparticle surface. The zeta potential of the nanoparticles decreased after they were coated with erythrocyte membranes (Figure 1H).

4.2 Cell viability

As shown in Figure 2A, after incubation with different concentrations of CS-gp90@M and CS-gp90@M-M nanoparticles for 24 h, the cell survival rate was more than

90%. CS-gp90@M and CS-gp90@M-M nanoparticles were insignificantly toxic to HD11 macrophages, indicating the high biocompatibility of the biomimetic nano-vaccine and its potential for use in clinical settings.

4.3 NO production and iNOS mRNA expression

Activated macrophages inhibit the invasion of pathogens by releasing several important effector molecules including NO, which can regulate the functional activity of macrophages and mediate immune and inflammatory responses (23). iNOS is an enzyme that uses the oxidative stress (free radical) of NO to assist macrophages against pathogens in the immune system (24). iNOS generates peroxynitrite to produce NO through interactions with superoxide free radicals, which is considered to be the first immune defense response of the host against invading pathogens, especially intracellular pathogens. This reaction occurs only after macrophages are stimulated and activated, thus producing a large amount of NO (25). In the present study, a significant increase in NO release from HD11 macrophages was seen when CS-gp90@M-M nanoparticles were used (Figure 2B). The effect of CS-gp90@M-M nanoparticles on iNOS mRNA levels was determined by qRT-PCR, as seen in




Figure 2C. CS-gp90@M-M nanoparticles significantly increased the mRNA level of iNOS in HD11 cells compared to the control, gp90, CS-gp90, and CS-gp90@M groups.

4.4 APC-targeting ability of the biomimetic nano-vaccine


In both cellular immunity and humoral immunity, the treatment and expression of pathogenicity-related antigens through APCs is an important process (26). Therefore, the phagocytosis of the biomimetic nano-vaccine by APCs is important for immune responses and immune protection (27, 28). In the present study, CS-gp90@M-M and CS-gp90@M nanoparticles were stained with DiD and phagocytosis of the mannose receptor-targeting biomimetic nanoparticles by APCs was evaluated to investigate the targeting ability of the mannose receptor biomimetic nanoparticles. HD11 macrophages were incubated with stained CS-gp90@M or CS-gp90@M-M nanoparticles and analyzed by laser confocal microscopy. As shown in Figure 3A, compared to the CS-gp90@M group, the CS-gp90@M-M group demonstrated more red fluorescence-stained nanoparticles near the blue nucleus, suggesting that more CS-gp90@M-M nanoparticles were engulfed by the

macrophages. Grafted mannose significantly improved the macrophage-targeting ability of the nanoparticles.

To quantitatively analyze the uptake of CS-gp90@M and CS-gp90@M-M nanoparticles by HD11 macrophages, cells and nanoparticles co-incubated in Petri dishes were analyzed using an animal *in vivo* imaging system (29). As shown in Figures 3B, C, the average fluorescence intensity of HD11 cells incubated with CS-gp90@M-M nanoparticles was higher than that of CS-gp90@M nanoparticles without mannose modification, suggesting that mannose modification promoted the phagocytosis of nanoparticles by macrophages.

4.5 Serum REV-specific antibody titers in chicks immunized with CS-gp90@M-M nanoparticles

In vivo antibody titers are an important indicator of drug immunogenicity (30). As illustrated in Figure 4, the REV serum antibodies in the CS-gp90@M-M group increased rapidly, especially after the second week following booster immunizations. The antibody titer increased significantly, whereas the REV serum antibody titer of the other groups was relatively low and increased slowly. The antibody titer in the CS-



gp90@M group was higher than that in the other 3 groups and the positive control. These results showed that mannose modification and encapsulation by erythrocyte membranes could dramatically increase REV-specific antibody titers.

4.6 Serum levels of cytokines in chicks immunized with the bionic nano-vaccine

Cytokines are a kind of protein or small molecule polypeptide that can transfer information between cells and has immune-regulating and other effects. Serum cytokine levels can reflect the immune response status in the body. As illustrated in Figures 4B, C, the serum levels of cytokines (IL-4 and IFN- γ) in the mice in the CS-gp90@M group were significantly greater than those in the mice in the CS-gp90, gp90, and PBS groups on day 21, indicating that erythrocyte membranes encapsulation could increase the activity of CS-gp90 NPs in inducing cytokine secretion in chicks and induce both Th1 and Th2-type immune responses. Serum IL-4 and IFN- γ levels in the CS-gp90@M-M group were remarkably higher than those in the CS-gp90@M, CS-gp90, gp90, and PBS groups on day 21, suggesting that CS-gp90@M-M NPs could increase both Th1 and Th2-type cytokine production.


4.7 Proportion of CD4⁺ and CD8⁺T lymphocytes, and the CD4⁺/CD8⁺ ratio

The proportion of CD4⁺ and CD8⁺ T lymphocytes and the CD4⁺/CD8⁺ ratio are key biomarkers that can reflect the function of T lymphocytes. As seen in Figure 4, compared to

other groups, the proportion of CD8⁺ T lymphocytes in the CS-gp90@M-M group was notably decreased ($P < 0.05$), whereas the percentage of CD4⁺T cells and the CD4⁺/CD8⁺ ratio increased significantly ($P < 0.05$). The percentage of CD8⁺T lymphocytes in the CS-gp90@M group was significantly decreased ($P < 0.05$), whereas the percentage of CD4⁺ T cells and the CD4⁺/CD8⁺ ratio was significantly higher than those in the PBS, gp90, and CS-gp90 groups ($P < 0.05$). Treatment with both CS-gp90@M-M and CS-gp90@M NPs could partially improve the immune response by enhancing T lymphocyte subsets in the immunized chicks.

4.8 Expression of immune-regulating genes in chicks immunized with CS-gp90@M-M NPs

The mRNA expression level of *IFN- γ* , *IL-4*, *IRF7*, *IFIH1*, *TLR3*, *viperin*, and *STAT1* were selected to evaluate the immune response of chicks immunized with CS-gp90@M and CS-gp90@M-M NPs. As shown in Figure 5, CS-gp90@M-M significantly upregulated *IFIH1*, *TLR3*, and *viperin* in the bursa and spleen ($P < 0.05$). The *IFIH1* gene especially was upregulated about 6 times compared to the PBS group ($P < 0.05$). The mRNA expression level of all genes in the CS-gp90@M group except for *IRF7* and *STAT1* group was significantly higher than that in PBS, gp90, and CS-gp90 groups ($P < 0.05$), indicating that the immune response in the CS-gp90@M group was significantly higher than that in the PBS, gp90, and CS-gp90 groups. Taken together, erythrocyte membrane encapsulation and mannose modification promoted immune responses to the nucleic acid vaccine.






FIGURE 6

Release and biodistribution of CS-gp90@M-M NPs *in vivo*. (A, B) *In vivo* fluorescence images of chicks and the attenuation of the fluorescent dyes over time (C–F) Direct imaging of excised organs. Live animal imaging of chicks. The vaccine formulation was stained using a Cy5.5 fluorescent dye and chicks were immunized with CS-gp90@M-M and CS-gp90@M NPs. Live-animal imaging and fluorescence intensity in chicks at 24, 48, 72, and 168 h after injection was determined using an *in vivo* optical imaging system (A, B). Direct imaging and fluorescence intensity of the bursa, spleens, and livers of the injected chicks was determined at 12, 24, 72, 120, and 168 h after injection (C–F).

4.9 Biodistribution of CS-gp90@M-M NPs in chicks

To determine the release and distribution of the NPs in chicks, CS-gp90@M-M and CS-gp90@M NPs stained with DiD were injected intramuscularly into chicks for immunization. At 24 h after injection, the fluorescence intensity at the injection site was obvious, which then decreased gradually over time. After 24 h, the fluorescence intensity decreased significantly in the chicks in the CS-gp90@M group but decreased slowly in the chicks in the CS-gp90@M-M group (Figures 6A, B).

In the case of most vaccines, except for those administered through the gastrointestinal tract, antigens migrate through the APCs to secondary lymphoid organs and are presented to T cells and B cells. After injecting the fluorescence-labeled biomimetic nano-vaccine, fluorescence was first observed in the liver and the intensity decreased gradually as the drug entered the bloodstream (Figures 6C–F). After 72 h of inoculation, the fluorescence intensity in the bursa of Fabricius was higher, indicating successful antigen presentation. Antigens that migrated to the lymph nodes were presented to T cells and B

cells to further initiate the immune response. Additionally, the fluorescence intensity in the spleens of chicks in the CS-gp90@M-M group was remarkably higher than those in the CS-gp90@M group within 24 h ($P < 0.05$), which may have been related to the targeting effect of mannose. In general, CS-gp90@M-M NPs could induce targeting, prolong the residence time of drugs in the bursa of Fabricius, and help achieve an effective and sustained immune response.

4.10 Protective effect of CS-gp90@M-M NPs

As shown in Figure 7, the mortality rate was the highest on the 3rd day after vaccination and was related to younger age, undeveloped immune systems, and the weak physique of the chicks. Similarly, on day 30 after vaccination, the mortality in each group was lower, and there were significant differences among the groups only in body weight, although the cumulative mortality of the chicks treated with CS-gp90@M-M NPs was the lowest. The results of the challenge test on day 15 after




FIGURE 7 Protective effect of CS-gp90@M-M NPs in chicks infected with REV. **(A)** Schematic diagram demonstrating the REV challenge. Vaccinated chicks were challenged with REV on the 3rd **(B)**, 15th **(C)**, and 30th **(D)** days after vaccination.

vaccination were as expected, and the cumulative mortality rate in the CS-G@M-M group was the lowest (20%). In general, the immunoprotective effect of the vaccine was primarily decided by adaptive immunity, which elicited a robust immune response 2–3 weeks after vaccination. These findings suggested the CS-

gp90@M-M nano-vaccine demonstrated immunoprotective effects against REV in the chicks.

Avian reticuloendotheliosis can induce immunosuppression and lead to growth-inhibition syndrome. The affected chicks usually show growth stagnation and progressive weight loss (31).




FIGURE 8 Analysis of potential *in vivo* toxicity. H&E staining of the lungs, heart, spleen, liver, and kidneys of vaccinated chicks on day 28 after immunization. Magnification: 100x, scale bars: 100 μ m.

Table S2 shows that CS-gp90@M-M NPs greatly improved the body weight of the chicks after the challenge, and CS-gp90@M NPs also improved the body weight of uninfected chicks. Thus, the nano-formulation using erythrocyte membranes and mannose could promote the immunoprotective effect of the nucleic acid vaccine synthesized in this study.

4.11 Evaluation of biomimetic nano-vaccine toxicity

To evaluate the safety of CS-gp90@M-M NPs as vaccine adjuvants, the potential toxicity of CS-gp90@M-M NPs in major organs was evaluated. The heart, lung, liver, spleen, and kidney were sectioned and subjected to H&E staining. Compared to the PBS group, the test group showed normal tissue structures with no significant inflammation or injury (Figure 8). The body weight is a crucial biomarker to evaluate the potential toxicity of CS-gp90@M-M NPs. As illustrated in Table S3, compared to the PBS group, the body weight of chicks in test group showed no significant difference (Figure 8). These results indicated that CS-gp90@M-M NPs did not cause distinct toxicity *in vivo*. Therefore, CS-gp90@M-M NPs showed good biocompatibility *in vivo* and demonstrated no toxicity when used as a vaccine-delivery vehicle.

5 Discussion

Macrophages are important immune cells in the body and play important anti-infection, anti-tumor, and immune-regulating roles (32). Macrophages uptake pathogens through phagocytosis. The determination of the efficiency of NP phagocytosis by macrophages is a commonly used method to evaluate the immune activity of nano-vaccines. Zhang constructed chitosan-based NPs loaded with spring viremia of carp virus (SVCV) DNA, then encapsulated them with membranes from teleost erythrocytes, and further modified them with a mannose moiety to produce CS-G@M-M NPs. They found that large amount of CS-G@M-M NPs was up taken by macrophages (33). In the current study, the intensity of red fluorescence-stained CS-gp90@M-M NPs near the blue nucleus was significantly higher than the intensity of red fluorescence in the CS-gp90@M group. The CLSM image results indicated that more CS-gp90@M-M NPs were internalized by the macrophages. In addition, the quantitative analysis of the uptake of CS-gp90@M and CS-gp90@M-M NPs by macrophages demonstrated that the average fluorescence intensity of HD11 cells incubated with CS-gp90@M-M NPs was higher than that of CS-gp90@M NPs without mannose modification. After modifying CS-gp90@M NPs with mannose, HD11 could phagocytose more antigens. This may have been due to the binding of mannose residues and mannose receptors on

the macrophage surface. The current results demonstrated that grafted mannose significantly improved the macrophage-targeting ability of NPs.

Immunoglobulin (Ig) is a protein produced by B cells and refers to a globulin with antibody (Ab) activity or chemical structure similar to that of antibody molecules (34). Immunoglobulin is a tetrapeptide chain structure composed of 2 identical light chains and 2 identical heavy chains connected by disulfide bonds between the chains. Ig can specifically bind to the corresponding antigen when the antigen stimulates the body's immune system. Igs are divided into 5 classes, namely, immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD), and immunoglobulin E (IgE). Among these, IgG is the most common, and most antibody reactions involve IgG-mediated effector functions (35). The presence of specific IgG in the serum represents the body's humoral immunity levels and indicates the body's immune status. Feng et al. encapsulated ovalbumin (OVA) in poly(lactic-co-glycolic acid) (PLGA) microspheres (MPs) and conjugated them with MAN-modified CS to produce MAN-R-targeting nano-MPs (MAN-CS-OVA-PLGA-MPs). The *in vivo* immune response of the MPs was investigated using a mouse model. The results demonstrated that MAN-CS-OVA-PLGA-MPs significantly increased OVA-specific IgG and IgG isotope antibody levels, suggesting that mannose modification significantly enhanced the humoral immune response of CS-OVA-PLGA-MPs (36). In the present study, the REV-specific IgG antibody titers in the immunized chicks in the CS-gp90@M treated group were significantly increased compared to chicks in the CS-gp90 treatment group, suggesting that erythrocyte membrane coating could promote humoral responses induced by CS-gp90. In addition, compared to the other groups, the serum REV-specific IgG antibody levels in the chicks in the CS-gp90@M-M group were significantly increased after the 2nd week following booster immunization, and higher antibody titers were maintained for a long time, indicating that CS-gp90@M-M NPs could induce higher levels of IgG antibodies than CS-gp90@M NPs. The current results demonstrated that mannose-modified erythrocyte membranes could upregulate the humoral response induced by CS-gp90@M NPs in chicks.

Th1 and Th2-type immune responses can be stimulated by T-cell factors and produce immune responses against pathogens invading host cells. IL-4 is considered a typical cytokine. It is produced by T-helper Th2 cells and is responsible for activating cytotoxic T cells (3, 37). It plays a key role in the development of T and B lymphocytes and in driving humoral immune responses and antibody production (38). IL-4 has an immunomodulatory effect on B cells, T cells, mast cells, macrophages, and hematopoietic cells (4, 39). IFN- γ is a pro-inflammatory cytokine secreted by natural killer cells and activated T cells and is indispensable for adaptive and innate immunity against viral, bacterial, and protozoan infections (12, 40). In the current study, CS-gp90@M-M NPs increased both Th1 and Th2-type cytokine production in

immunized chicks, indicating that CS-gp90@M-M NPs significantly induced a balanced Th1/Th2 immune response. The present results also suggested that mannose modification could increase the stimulation of cytokine secretion by CS-gp90@M NPs in chicks and induce both Th1 and Th2-type immune responses.

T lymphocyte subsets play a crucial role in immune modulation and can be divided into Th lymphocytes and suppressor lymphocytes (41). As a marker of Th lymphocytes, CD4⁺ antigens can stimulate B cells to produce antibodies (42, 43). CD8⁺ can reflect the level of cellular immune response (44). In the humoral immune response, there is an increase in CD4⁺ cell numbers, a decrease in CD8⁺ cell numbers, and an increase in the CD4⁺/CD8⁺ ratio (45). In the present study, CS-gp90@M and CS-gp90@M-M NPs significantly increased the proportion of CD4⁺T cells and the CD4⁺/CD8⁺ ratio, whereas they decreased the proportion of CD8⁺ T lymphocytes. Therefore, both CS-gp90@M-M and CS-gp90@M NP treatments could partially promote the immune response by enhancing T lymphocyte subsets in immunized chicks. The effect of CS-gp90@M-M NPs was more pronounced than that of CS-gp90@M NPs, indicating that mannose-targeted NPs could promote the transmission of bionic NPs in T cell subsets. The present results revealed that mannose-modified erythrocyte membrane coating may be an effective way to improve the efficacy of nano-vaccines in activating T cell subsets in chicks.

During virus infection or vaccine injection in chicks, a series of immune responses occur, and important genes related to immune responses play a key role in the immune response process. IFN- γ and IL-4 are important immunoregulatory cytokines. IFN- γ is a Th1 cytokine, which mainly performs the function of promoting cellular immunity. IL-4 is a Th2 cytokine, which has the primary function of promoting humoral immunity (46). TLR3 is the main receptor in chicks that helps to recognize RNA viruses (47). *IFIH1* are mainly related to the virus response, innate immune response, and the control of apoptosis (17). Viral infections can induce the high expression of *IRF7* (48), and high expression of *STAT1* is observed in response to IFN (49). Viperin is a virus-inhibitory protein (50). In the present study, the mRNA expression level of *IFN- γ* , *IL-4*, *IRF7*, *IFIH1*, *TLR3*, *viperin*, and *STAT1* was determined to evaluate the immune response of chicks immunized with CS-gp90@M and CS-gp90@M-M NPs. The results showed that CS-gp90@M-M NPs significantly increased the expression levels of *IFIH1*, *TLR3*, and *viperin* in the bursa and spleen. Interestingly, the *IFIH1* gene was upregulated about 6 times compared to the PBS group, indicating that CS-gp90@M-M NPs could induce stronger immune responses in secondary immune organs, which could help to prevent viral infections. The results also demonstrated that the mRNA level of *IFN- γ* , *IL-4*, *IFIH1*, *TLR3*, and *viperin* in the CS-gp90@M group was significantly higher than in the PBS, gp90, and CS-gp90 groups, indicating that erythrocyte membrane encapsulation and mannose modification could promote immune responses to the nucleic acid vaccine. In

addition, the upregulated expression of immune-related genes in the spleen was found to be higher than that in the bursa of Fabricius due to the presence of more APCs in the spleen.

The cumulative release properties of an antigen or adjuvant are key features reflecting the function of an antigen delivery system. Live-animal imaging methods are commonly used to analyze the release characteristics of fluorescently labeled antigens delivered from the injection site, and the fluorescence imaging of isolated main organs and tissues can represent the *in vivo* biodistribution of fluorescently labeled NPs at different time points (51). In the current experiment, the fluorescence intensity of DiD-stained CS-gp90@M-M and CS-gp90@M NPs at the injection site was obvious at 12 h and then decreased gradually over time. After 24 h, the fluorescence intensity decreased remarkably at the injection site in the chicks in the CS-gp90@M group but was slowly attenuated in the chicks in the CS-gp90@M-M group.

During the process of vaccination to trigger an immune response, antigens are taken up by APCs, migrate to secondary lymphoid organs and are presented to T cells and B cells. In the present study, the fluorescence intensity of DiD-labeled CS-gp90@M-M and CS-gp90@M NPs was first measured in the liver 12 h after injection and the fluorescence intensity gradually decreased over time. The fluorescence intensity in the bursa of Fabricius was observed from 12 h to 168 h, suggesting that the antigen was successfully presented in secondary immune organs. Antigens that migrated to the lymph nodes were presented to T cells and B cells, to further initiate the immune response. The intensity in the chicks in the CS-gp90@M-M group at 168 h was notably higher than in the CS-gp90@M group, indicating that CS-gp90@M-M NPs had stronger sustained release in immune organs. Furthermore, the fluorescence intensity in the spleens in the CS-gp90@M-M group was remarkably higher than that in the CS-gp90@M group within 24 h, which may have been due to the targeting effect of mannose modification. Taken together, CS-gp90@M-M NPs could achieve targeting, prolong the residence time of drugs in the bursa of Fabricius, and elicit a stronger and sustained immune response compared to the other groups.

An ideal vaccine elicits a robust immune response 2–3 weeks after vaccination, and the determination of the immunoprotective ratio is a method commonly used to assess vaccine immune responses (52). In this study, the mortality rate was the highest on the 3rd day after vaccination. The mortality in each group was lower on day 30 after vaccination, and there were significant differences among the groups only in body weight, although the cumulative mortality of the chicks treated with CS-gp90@M-M NPs was the lowest. The challenge test results on day 15 after vaccination were as expected, and the cumulative mortality rate in the CS-G@M-M group was the lowest (20%). The current data indicated a notable immunoprotective effect in the chicks in the CS-gp90@M-M NP-immunized group given a REV challenge. This may have been due to mannose decorated on CS-gp90@M NPs to increase the immunoprotective effects of this vaccine.

6 Conclusions

In summary, for the first time in the field, we investigated the immune response of mannose-modified avian erythrocyte membrane-encapsulated NPs as a novel biomimetic drug delivery system with a characteristic core-shell structure as a biomimetic nano-vaccine. The results showed that bionic encapsulation with erythrocyte membranes and mannose-targeting modification significantly improved the phagocytosis ability of macrophages and induced immune response *in vivo* and *in vitro*. In addition, this chitosan-based novel delivery system could carry plasmid DNA and induce immunoprotective responses after the challenge. Therefore, red blood membranes as a biomimetic targeted modification material enhanced the immune response against REV, and mannose-modified erythrocyte membrane decorating may be an effective strategy for the development of nano-vaccine systems for use against several poultry diseases.

Data availability statement

The original contributions presented in the study are included in the article/[Supplementary Materials](#). Further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Southwest Minzu University.

Author contributions

Investigation, HF and YF. Conceptualization, YF and HF. Methodology, YF, ZL and DW. Software, YF. Validation, LZ and

QL. Formal analysis, DW. Data curation, QL, SL, DW, FT and HL. Writing—original draft preparation, YF. Writing—review and editing, funding acquisition, project administration, HF. All authors contributed to the article and approved the submitted version.

Funding

The project was supported by the National Natural Science Foundation of China (Project No. 31872511) and in part by the Applied Basic Research Program of Sichuan Province (Project No. 2021YJ0289) and in part by Initial Foundation of Scientific Research for the Introduction of Talents (Project No. RQD2021075).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.1066268/full#supplementary-material>

References

1. Woźniakowski G, Frant M, Mamczur A. Avian reticuloendotheliosis in chickens - an update on disease occurrence and clinical course. *J Vet Res* (2018) 62(3):257–60. doi: 10.2478/jvetres-2018-0036
2. Sun M, Li X, Cao H, Wang Y, Zheng SJ. Development of monoclonal antibodies against the gp90 protein of reticuloendotheliosis virus and mapping of their recognition regions. *Sheng Wu Gong Cheng Xue Bao* (2015) 31(1):75–85.
3. Chaudhari R, Tandel N, Sahu K, Negi S, Bashir H, Rupareliya A, et al. Transdermal immunization of elastic liposome-laden recombinant chimeric fusion protein of p. falciparum (PfMSP-Fu24) mounts protective immune response. *Nanomaterials (Basel Switzerland)* (2021) 11(2):406. doi: 10.3390/nano11020406
4. Tyagi RK, Garg NK, Jadon R, Sahu T, Katare OP, Dalai SK, et al. Elastic liposome-mediated transdermal immunization enhanced the immunogenicity of p. falciparum surface antigen, MSP-119. *Vaccine* (2015) 33(36):4630–8. doi: 10.1016/j.vaccine.2015.06.054
5. Rajput A, Mandlik S, Pokharkar V. Nanocarrier-based approaches for the efficient delivery of anti-tubercular drugs and vaccines for management of tuberculosis. *Front Pharmacol* (2021) 12:749945. doi: 10.3389/fphar.2021.749945
6. Ganassi M, Zammit PS. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cellopathies. *Eur J Transl Myol* (2022) 32(1):10064. doi: 10.4081/ejtm.2022.10064
7. Nazemidashtarjandi S, Sharma VM, Puri V, Farnoud AM, Burdick MM. Lipid composition of the cell membrane outer leaflet regulates endocytosis of nanomaterials through alterations in scavenger receptor activity. *ACS Nano* (2022) 16(2):2233–48. doi: 10.1021/acsnano.1c08344

8. Ren Y, Miao C, Tang L, Liu Y, Ni P, Gong Y, et al. Homotypic cancer cell membranes camouflaged nanoparticles for targeting drug delivery and enhanced chemo-photothermal therapy of glioma. *Pharm (Basel)* (2022) 15(2):157. doi: 10.3390/ph15020157
9. Jiang Y, Krishnan N, Zhou J, Chekuri S, Wei X, Kroll AV, et al. Engineered cell-Membrane-Coated nanoparticles directly present tumor antigens to promote anticancer immunity. *Adv Mater* (2020) 32(30):e2001808. doi: 10.1002/adma.202001808
10. Ross M, Ofri R. The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. *Neural Regen Res* (2021) 16(9):1751–9. doi: 10.4103/1673-5374.306063
11. Garg NK, Dwivedi P, Campbell C, Tyagi RK. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention. *Eur J Pharm Sci* (2012) 47(5):1006–14. doi: 10.1016/j.ejps.2012.09.012
12. Hamed H, Moradi S, Hudson SM, Tonelli AE, King MW. Chitosan based bioadhesives for biomedical applications: A review. *Carbohydr Polym* (2022) 282:119100. doi: 10.1016/j.carbpol.2022.119100
13. Balusamy SR, Rahimi S, Sukweenadhi J, Sunderraj S, Shanmugam R, Thangavelu L, et al. Chitosan, chitosan nanoparticles and modified chitosan biomaterials, a potential tool to combat salinity stress in plants. *Carbohydr Polym* (2020) 284:119189. doi: 10.1016/j.carbpol.2022.119189
14. Yu J, Wang P, Yin M, Zhang K, Wang X, Han B. Carboxymethyl chitosan-grafted polyvinylpyrrolidone-iodine microspheres for promoting the healing of chronic wounds. *Bioengineered* (2022) 13(4):8735–46. doi: 10.1080/21655979.2022.2054911
15. Gupta MK, Sansare V, Shrivastava B, Jadhav S, Gurav P. Fabrication and evaluation of mannose decorated curcumin loaded nanostructured lipid carriers for hepatocyte targeting: *In vivo* hepatoprotective activity in wistar rats. *Curr Res Pharmacol Drug Discovery* (2022) 3:100083. doi: 10.1016/j.crphar.2022.100083
16. Thean RK, Ong DX, Heng ZS, Gan SK, Yeo JY. To plate or to simply unfreeze, that is the question for optimal plasmid extraction. *J Biomol Tech* (2021) 32(2):57–62. doi: 10.7171/jbt.20-3203-001
17. Zhang S, Chu C, Wu Z, Liu F, Xie J, Yang Y, et al. IFIH1 contributes to M1 macrophage polarization in ARDS. *Front Immunol* (2021) 11:580838. doi: 10.3389/fimmu.2020.580838
18. Brunauer LS, Chen JY, Koontz MZ, Davis KK, O'Brien LE, Wright EM, et al. Extraction of phospholipids from human erythrocyte membranes by hemoglobin oxidation products. *J Membr Biol* (2016) 249(3):305–17. doi: 10.1007/s00232-016-9869-2
19. Hamner KL, Alexander CM, Coopersmith K, Reishofer D, Provenza C, Maye MM. Using temperature-sensitive smart polymers to regulate DNA-mediated nanoassembly and encoded nanocarrier drug release. *ACS Nano* (2013) 7(8):7011–20. doi: 10.1021/nn402214e
20. Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. *Cold Spring Harb Protoc* (2018) 2018(6):469–71. doi: 10.1101/pdb.prot095505
21. Grant R, Coopman K, Silva-Gomes S, Campbell JJ, Kara B, Braybrook J, et al. Assessment of protocol impact on subjectivity uncertainty when analyzing peripheral blood mononuclear cell flow cytometry data files. *Methods Protoc* (2021) 4(2):24. doi: 10.3390/mps4020024
22. Moore JP, Zhang SL, Nieuwoudt H, Divol B, Trygg J, Bauer FF. A multivariate approach using attenuated total reflectance mid-infrared spectroscopy to measure the surface mannoproteins and β -glucans of yeast cell walls during wine fermentations. *J Agric Food Chem* (2015) 63(45):10054–63. doi: 10.1021/acs.jafc.5b03154
23. Titov VY, Dolgorukova AM, Vertiprakhov VG, Ivanova AV, Osipov AN, Slesarenko NA, et al. Synthesis and metabolism of nitric oxide (NO) in chicken embryos and in the blood of adult chicken. *Bull Exp Biol Med* (2020) 168(3):321–5. doi: 10.1007/s10517-020-04700-4
24. Wu D, Liu Z, Feng Y, Tang F, Li S, Zhang X, et al. Development and characterization of DEC-205 receptor targeted potentilla anserina l polysaccharide PLGA nanoparticles as an antigen delivery system to enhance *in vitro* and *in vivo* immune responses in mice. *Int J Biol Macromolecules* (2022). S0141-8130(22) 02426-6. doi: 10.1016/j.ijbiomac.2022.10.184
25. Liu J, Zhang Y, Sheng H, Liang C, Liu H, Moran Guerrero JA, et al. Hyperoside suppresses renal inflammation by regulating macrophage polarization in mice with type 2 diabetes mellitus. *Front Immunol* (2021) 12:733808. doi: 10.3389/fimmu.2021.733808
26. Wang F, Ullah A, Fan X, Xu Z, Zong R, Wang X, et al. Delivery of nanoparticle antigens to antigen-presenting cells: from extracellular specific targeting to intracellular responsive presentation. *J Control Release* (2021) 333:107–28. doi: 10.1016/j.jconrel.2021.03.027
27. Burster T. Processing and regulation mechanisms within antigen presenting cells: a possibility for therapeutic modulation. *Curr Pharm Des* (2013) 19(6):1029–42. doi: 10.2174/1381612811319060005
28. Miura R, Sawada SI, Mukai SA, Sasaki Y, Akiyoshi K. Antigen delivery to antigen-presenting cells for adaptive immune response by self-assembled anionic polysaccharide nanogel vaccines. *Biomacromolecules* (2020) 21(2):621–9. doi: 10.1021/acs.biomac.9b01351
29. Choi ES, Song J, Kang YY, Mok H. Mannose-modified serum exosomes for the elevated uptake to murine dendritic cells and lymphatic accumulation. *Macromol Biosci* (2019) 19(7):e1900042. doi: 10.1002/mabi.201900042
30. Ihara H, Miyachi M, Imafuku S. Relationship between serum anti-varicella zoster virus antibody titer and time from onset of herpes zoster. *J Dermatol* (2018) 45(2):189–93. doi: 10.1111/1346-8138.14168
31. Li M, Wang P, Li Q, Deng Q, Shi M, Mo M, et al. Reemergence of reticuloendotheliosis virus and marek's disease virus co-infection in yellow-chickens in southern China. *Poult Sci* (2021) 100(8):101099. doi: 10.1016/j.psj.2021.101099
32. Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. *Cancer Res* (2021) 81(5):1201–8. doi: 10.1158/0008-5472.CAN-20-2990
33. Zhang C, Zhang PQ, Guo S, Chen G, Zhao Z, Wang GX, et al. Application of biomimetic cell-derived nanoparticles with mannose modification as a novel vaccine delivery platform against teleost fish viral disease. *ACS Biomaterials Sci Eng* (2020) 6(12):6770–7. doi: 10.1021/acsbomaterials.0c01302
34. Bruzeau C, Cook-Moreau J, Pinaud E, Le Noir S. Contribution of immunoglobulin enhancers to b cell nuclear organization. *Front Immunol* (2022) 13:877930. doi: 10.3389/fimmu.2022.877930
35. Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. *Front Immunol* (2021) 12:613530. doi: 10.3389/fimmu.2021.613530
36. Feng H, Yang X, Zhang L, Liu Q, Feng Y, Wu D, et al. Mannose-modified chitosan poly(lactic-co-glycolic acid) microspheres act as a mannose receptor-mediated delivery system enhancing the immune response. *Polymers* (2021) 13(12):2208. doi: 10.3390/polym1312208
37. Kubo M. The role of IL-4 derived from follicular helper T (TFH) cells and type 2 helper T (TH2) cells. *Int Immunol* (2021) 33(12):717–22. doi: 10.1093/intimm/dxab080
38. Duan L, Liu D, Chen H, Mintz MA, Chou MY, Kotov DI, et al. Follicular dendritic cells restrict interleukin-4 availability in germinal centers and foster memory b cell generation. *Immunity* (2021) 54(10):2256–2272.e6. doi: 10.1016/j.immuni.2021.08.028
39. Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. *Fac Rev* (2021) 10:71. doi: 10.12703/r/10-71
40. Seo SG, Ahn YJ, Jin MH, Kang NG, Cho HS. Curcuma longa enhances IFN- γ secretion by natural killer cells through cytokines secreted from macrophages. *J Food Sci* (2021) 86(8):3492–504. doi: 10.1111/1750-3841.15821
41. Li J, Tan J, Martino MM, Lui KO. Regulatory T-cells: Potential regulator of tissue repair and regeneration. *Front Immunol* (2018) 9:585. doi: 10.3389/fimmu.2018.00585
42. Ruterbusch M, Pruner KB, Shehata L, Pepper M. *In vivo* CD4+ T cell differentiation and function: Revisiting the Th1/Th2 paradigm. *Annu Rev Immunol* (2020) 38:705–25. doi: 10.1146/annurev-immunol-103019-085803
43. Raphael I, Joern RR, Forsthuber TG. Memory CD4+ T cells in immunity and autoimmune diseases. *Cells* (2020) 9(3):531. doi: 10.3390/cells9030531
44. Reina-Campos M, Scharping NE, Goldrath AW. CD8+ T cell metabolism in infection and cancer. *Nat Rev Immunol* (2021) 21(11):718–38. doi: 10.1038/s41577-021-00537-8
45. Jang JY, Choi GH, Ji S. IFN- γ or IL-4 polarization impacts the response of gingival fibroblasts to oral bacteria. *J Periodontol Res* (2021) 56(3):462–70. doi: 10.1111/jre.12837
46. Raphael I, Kumar R, McCarl LH, Shoger K, Wang L, Sandesh P, et al. TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in glioblastoma. *Front Immunol* (2021) 12:637146. doi: 10.3389/fimmu.2021.637146
47. Chen Y, Lin J, Zhao Y, Ma X, Yi H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. *J Zhejiang Univ Sci B* (2021) 22(8):609–32. doi: 10.1631/jzus.B2000808
48. Li S, Zhu Z, Yang F, Cao W, Yang J, Ma C, et al. Porcine epidemic diarrhea virus membrane protein interacted with IRF7 to inhibit type I IFN production during viral infection. *J Immunol* (2021) 206(12):2909–23. doi: 10.4049/jimmunol.2001186
49. Zuo Y, Feng Q, Jin L, Huang F, Miao Y, Liu J, et al. Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling. *Nat Commun* (2020) 11(1):1146. doi: 10.1038/s41467-020-14948-z
50. Rivera-Serrano EE, Gizzi AS, Arnold JJ, Grove TL, Almo SC, Cameron CE. Viperin reveals its true function. *Annu Rev Virol* (2020) 7(1):421–46. doi: 10.1146/annurev-virology-011720-095930

51. Wu J, Luo FL, Xie Y, Xiong H, Gao Y, Liu G, et al. EST12 regulates myc expression and enhances anti-mycobacterial inflammatory response *via* RACK1-JNK-AP1-Myc immune pathway. *Front Immunol* (2022) 13:943174. doi: 10.3389/fimmu.2022.943174

52. Van der Ley PA, Zariri A, van Riet E, Oosterhoff D, Kruiswijk CP. An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. *Front Immunol* (2021) 12:781280. doi: 10.3389/fimmu.2021.781280